Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

SPB vs SKIN: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

SPB Wins Head-to-Head Institutional Verdict (3–3 across 6 Pillars · 8–2 Matrix Metrics)

SPB Overall Winner 6-Pillar Tally: SPB 3 – 3 SKIN Matrix Metrics: SPB 8 – 2 SKIN

As of Nov 16, 2026, Spectrum Brands Holdings, Inc. (SPB) is the stronger overall head-to-head candidate over The Beauty Health Company (SKIN) in the Tradestie Institutional Equity Comparison Engine, winning 8–2 core matrix metrics and 3–3 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, Balance Sheet & Cash Flow). SPB carries a Unified Composite Score of 39.5/100 (SELL) at $83.76 (14.5x Forward P/E, 7.5% operating margin), whereas SKIN carries 34.1/100 (SELL) at $15.05 (106.4x Forward P/E, 2.4% operating margin).

  • Defensive Composite Rating Caution: Although SPB compares more favorably head-to-head, both SPB (39.5/100 SELL) and SKIN (34.1/100 SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model.
  • Technical & Structure Timing Caution: SPB is currently in a Weinstein Distribution regime near a flattening 50-day moving average (RSI 48.2); meanwhile SKIN trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 67.4). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About SPB vs SKIN
SPB NYSE Head-to-Head Winner
Spectrum Brands Holdings, Inc.
Miscellaneous Electrical Machinery, Equipment & Supplies
$83.76
-4.66% 1D
Market Cap $2.0B
TTM Revenue $2.85B
Forward P/E 14.5x
Beta / 30D Vol 0.96β · 43% Vol
Unified Composite Score
39.5 / 100 SELL
Tech 44.0 Fund 47.0 Flow 50.0 Mom 50.0
Weinstein Technical Phase Distribution · Trim / tighten stop
Price near a flattening SMA50 (slope -1.8%) with fading momentum, RSI 48
RSI-14: 48.2 · SMA20: $84.53 · SMA50: $82.94
SKIN NASDAQ
The Beauty Health Company Class A Common Stock
Surgical & Medical Instruments & Apparatus
$15.05
-7.73% 1D
Market Cap $106.3M
TTM Revenue $289M
Forward P/E 106.4x
Beta / 30D Vol -14.22β · 192% Vol
Unified Composite Score
34.1 / 100 SELL
Tech 50.0 Fund 34.0 Flow 67.0 Mom 46.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (314.8% over 20 days), RSI 67
RSI-14: 67.4 · SMA20: $12.50 · SMA50: $6.24

6-Pillar Scorecard Institutional Category Breakdown (SPB 3 – 3 SKIN)

Columns: Metric · SPB · SKIN
1. Valuation Multiples SPB
Forward P/E 14.5x 106.4x
Trailing P/E 39.9x 106.4x
PEG Ratio 1.36x 0.93x
EV / Revenue 0.7x 0.9x
2. Growth & Scale SKIN
Revenue Growth (YoY) -2.8% -2.1%
Earnings Growth (YoY) -51.3% +0.0%
TTM Revenue (USD) $2.85B $289M
Market Cap $2.0B $106.3M
3. Profitability & Quality SPB
Gross Margin 40.3% 67.2%
Operating Margin 7.5% 2.4%
Net Profit Margin 1.7% -6.3%
Return on Equity (ROE) 3.0% -30.1%
4. Balance Sheet & Cash Flow SPB
Cash Generation (TTM) $315M EBITDA $17M
Cash Flow Margin 11.0% EBITDA Mgn 5.8%
Net Cash / Leverage $81.38 Book/Sh · 3.0% ROE $161M Net Debt (6.61x D/E)
Dividend Yield 2.13% None (0.00%)
5. Options & Positioning SKIN
Options Structure Phase UNCLASSIFIED UNCLASSIFIED
Current IV / %ile 37.0% (7th %ile) 517.4% (100th %ile)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase NEUTRAL · Distribution NEUTRAL · Markup
6. R&D & Supply-Chain Moat SKIN
OpEx & R&D Intensity 32.8% of Rev ($936M) 64.8% of Rev ($187M)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Household & Personal Products Operator Household & Personal Products Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: SPB (8) vs SKIN (2)
Institutional Metric SPB SKIN Criterion Row Edge
Market Capitalization
Scale
$2.0B $106.3M Larger Scale SPB
Trailing P/E Ratio
Valuation
39.9x 106.4x Lower Multiple SPB
Forward P/E Ratio
Valuation
14.5x 106.4x Lower Multiple SPB
Revenue Growth (YoY)
Growth
-2.8% -2.1% Higher Growth SKIN
Operating Margin (TTM)
Profitability
7.5% 2.4% Higher Margin SPB
Net Profit Margin
Profitability
1.7% -6.3% Higher Margin SPB
Return on Equity (ROE)
Capital Efficiency
3.0% -30.1% Higher ROE SPB
52-Week Range Position
Momentum
67% ($53–$99) 83% ($0–$18) Stronger Trend SKIN
Beta / 30D Volatility
Risk Regime
0.96β · 43% Vol -14.22β · 192% Vol Lower Realized Risk SPB
Unified Institutional Score
Composite Signal
39.5 / 100 (SELL) 34.1 / 100 (SELL) Higher Composite SPB
Trailing 12M Revenue (USD)
Operating Scale
$2.85B $289M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
40.3% 67.2% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
1.36x PEG · 0.7x EV/Rev 0.93x PEG · 0.9x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
$315M EBITDA ($81.38 Book/Sh · 3.0% ROE) $17M ($161M Net Debt (6.61x D/E)) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon SKIN +36.51 pp
SPB: +6.01% · SKIN: +42.52%
3M Horizon SKIN +2413.15 pp
SPB: -4.82% · SKIN: +2408.33%
6M Horizon SKIN +2376.49 pp
SPB: +8.65% · SKIN: +2385.14%
1Y Horizon SKIN +1014.29 pp
SPB: +43.4% · SKIN: +1057.69%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on SPB vs SKIN. Trailing 12-month operating profitability (SPB 7.5% vs SKIN 2.4%) and valuation multiples (SPB 14.5x vs SKIN 106.4x Forward P/E) are benchmarked directly in Pillar 4 below.

SPB ADR TTM Benchmark FX-Normalized USD
TTM Revenue$2.85B
Gross Margin40.3%
Op. Margin7.5%
ROE / Fwd P/E3.0% · 14.5x
SKIN ADR TTM Benchmark FX-Normalized USD
TTM Revenue$289M
Gross Margin67.2%
Op. Margin2.4%
ROE / Fwd P/E-30.1% · 106.4x

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
SPB UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 37.0%
IV Percentile 7th %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact SPB Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
SKIN UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 517.4%
IV Percentile 100th %ile
Put/Call OI Skew N/A
IV Regime Extreme (>80th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BEARISH
OBV Flow NEUTRAL
Exact SKIN Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
SPB Moat Profile Cyclical / Execution-Driven Positioning
Household & Personal Products Operator
Competes within the Household & Personal Products value chain with $2.0B market capitalization and 7.5% operating margin.
OpEx & R&D Reinvestment 32.8% of Rev ($936M)
90D Engineering Disclosures 0 Published
SKIN Moat Profile Cyclical / Execution-Driven Positioning
Household & Personal Products Operator
Competes within the Household & Personal Products value chain with $106.3M market capitalization and 2.4% operating margin.
OpEx & R&D Reinvestment 64.8% of Rev ($187M)
90D Engineering Disclosures 0 Published

Investor FAQ SPB vs SKIN Key Questions & Quantitative Answers

As of Nov 16, 2026, Spectrum Brands Holdings, Inc. (SPB) is the stronger overall head-to-head candidate over The Beauty Health Company (SKIN) in the Tradestie Institutional Equity Comparison Engine, winning 8–2 core matrix metrics and 3–3 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, Balance Sheet & Cash Flow). SPB carries a Unified Composite Score of 39.5/100 (SELL) at $83.76 (14.5x Forward P/E, 7.5% operating margin), whereas SKIN carries 34.1/100 (SELL) at $15.05 (106.4x Forward P/E, 2.4% operating margin). Defensive Composite Rating Caution: Although SPB compares more favorably head-to-head, both SPB (39.5/100 SELL) and SKIN (34.1/100 SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model. Technical & Structure Timing Caution: SPB is currently in a Weinstein Distribution regime near a flattening 50-day moving average (RSI 48.2); meanwhile SKIN trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 67.4). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

SKIN leads the Growth & Scale pillar: SPB posts -2.8% YoY revenue growth and -51.3% YoY earnings growth on $2.85B TTM revenue (40.3% gross margin, 7.5% operating margin), compared with SKIN at -2.1% YoY revenue growth and +0.0% YoY earnings growth on $289M TTM revenue (67.2% gross margin, 2.4% operating margin). On trailing 12-month operating scale, SPB generates $2.85B in USD-normalized revenue versus $289M for SKIN. In operating R&D and SG&A reinvestment, SPB deploys 32.8% of Rev ($936M) (0 90-day corporate R&D disclosures) versus 64.8% of Rev ($187M) (0 disclosures) for SKIN.

SPB screens cheaper on headline valuation multiples. SPB trades at 14.5x Forward P/E, 39.9x Trailing P/E, 1.36x PEG, and 0.7x EV/Revenue (11.0% EBITDA margin), whereas SKIN trades at 106.4x Forward P/E, 106.4x Trailing P/E, 0.93x PEG, and 0.9x EV/Revenue (5.8% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against SPB (3.0% ROE) versus SKIN (-30.1% ROE) capital efficiency.

In options market volatility and institutional positioning, SPB carries 37.0% implied volatility (7th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.96β · 43% Vol realized risk). By comparison, SKIN carries 517.4% implied volatility (100th %ile, Extreme (>80th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (-14.22β · 192% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.